NCT02760316View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

September 11, 2017

Study Completion Date

September 11, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

AZD9567 10 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 20 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 40 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 80 mg

Oral suspension Multiple doses 5 days of treatment Once daily

DRUG

Prednisolone 20 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 125 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

AZD9567 155 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

Prednisolone 5 mg

Oral Multiple doses 5 days of treatment Once daily

DRUG

Prednisolone 40 mg

Oral Multiple doses 5 days of treatment Once daily

Trial Locations (2)

14050

Research Site, Berlin

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY